

B1  
Cncld.

analogues used in the inventive method. Such super-promiscuous epitopes will allow for the most simple embodiments of the invention wherein only one single modified amyloidogenic polypeptide is presented to the vaccinated animal's immune system.

---

Please replace the paragraph beginning on page 58, line 6 with the following amended paragraph:

---

B2

It should be noted that preferred modified amyloidogenic molecules comprises modifications which results in a polypeptide having a sequence identity of at least 70% with an amyloidogenic protein or with a subsequence thereof of at least 10 amino acids in length. Higher sequence identities are preferred, e.g. at least 75% or even at least 80, 85, 90 or 95%. The sequence identity for proteins and nucleic acids can be calculated as  $(N_{\text{ref}} - N_{\text{dif}}) \cdot 100 / N_{\text{ref}}$ , wherein  $N_{\text{dif}}$  is the total number of non-identical residues in the two sequences when aligned and  $N_{\text{ref}}$  is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC (SEQ ID NO:17) will have a sequence identity of 75% with the sequence AATCAATC (SEQ ID NO:18) ( $N_{\text{dif}}=2$  and  $N_{\text{ref}}=8$ ).

---

Please replace the Sequence Listing filed February 20, 2001 located immediately after the claims with the substitute Sequence Listing enclosed herewith.